Compare
Greenwich LifeSciences, Inc. vs Vyome Holdings, Inc vs Kairos Pharma, Ltd. vs Ernexa Therapeutics Inc.
| Latest fiscal year | Greenwich LifeSciences, Inc. GLSI | Vyome Holdings, Inc HIND | Kairos Pharma, Ltd. KAPA | Ernexa Therapeutics Inc. ERNA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $319.7K | n/a | n/a |
| Revenue growth (YoY) | n/a | +24.4% | n/a | n/a |
| Gross margin | n/a | 68.4% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$19.36M | -$10.26M | -$5.45M | -$14.08M |
| EPS (Diluted) | -$1.43 | -$4.86 | -$0.30 | -$2.24 |
| Operating cash flow | -$9.91M | -$3.75M | -$3.44M | -$7.02M |
| Free cash flow | n/a | n/a | n/a | -$7.05M |
| Cash & equivalents | $6.18M | $4.98M | $4.49M | n/a |
| Total assets | $6.18M | $6.50M | $6.54M | $5.83M |
| Total liabilities | $5.82M | $2.74M | n/a | $3.43M |
| Shareholders' equity | $353.2K | $3.76M | $6.34M | $2.40M |
| Return on year-end equity | n/m | -272.8% | -85.9% | -586.6% |
| Shares outstanding | 14.30M | 5.92M | 20.82M | 7.85M |
Revenue, most recent five fiscal years
| Fiscal year | Greenwich LifeSciences, Inc. | Vyome Holdings, Inc | Kairos Pharma, Ltd. | Ernexa Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $319.7K Ended 2025-12-31 | n/a | $582.0K Ended 2024-12-31 |
| 1 year earlier | n/a | $256.9K Ended 2024-12-31 | n/a | $68.0K Ended 2023-12-31 |
| 2 years earlier | n/a | $8.68M Ended 2023-12-31 | n/a | $0 Ended 2022-12-31 |
| 3 years earlier | n/a | $11.24M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $13.60M Ended 2021-12-31 | n/a | $5.80M Ended 2020-12-31 |